INNOVATION

INcipieNt to OVert Angiotensin II receptor blocker, Telmisartan, Investigation On type II diabetic Nephropathy

INNOVATION examined the renoprotective effects of MICARDIS^® in Japanese patients measuring the transition rate decrease from incipient to overt nephropathy

Why conduct this study?

Diabetic nephropathy has gained recognition as the leading cause of end-stage renal disease (ESRD) in Europe, the USA, and in Japan.

On the basis of clinical trial outcomes, primarily undertaken in Caucasian patients, angiotensin II receptor blockers (ARBs) are now established renoprotective agents and are recommended as first-line treatment in type 2 diabetes with nephropathy.^1-5

The appearance of albumin in the urine is a sign of deteriorating kidney function. Thus, proteinuria is one of the most important markers for disease severity in diabetic nephropathy.

Results from dose comparison studies can be used to guide the initiation of optimal treatment regimens.

Data show that Japanese patients are particularly susceptible to diabetic nephropathy and ESRD⁶ and the aim of the INNOVATION study was to demonstrate that high and low doses of MICARDIS^® delay the onset of overt nephropathy in Japanese patients with diabetes and microalbuminuria.^7,8

References